Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Latest news

12/25/2020 Analysis of Intersections Occurring when Pharmacies Cooperate with More than One Pharmacy Association (Q1 – Q3 2020)

While working with pharmacy associations, manufacturing companies and therefore, customers of marketing activities will inevitably have to face the following issue: some pharmacies cooperate with more than one association, which leads to the duplication of sales in the accounting reports. That, in turn, leads to the problem of fair settlements with associations, which could then result in incorrect planning and accounting distortion between different departments, as well as bring complications when assigning tasks to medical representatives, etc.

12/24/2020 Pharmaceutical Drug Production in Russia (November 2020)

Between January and November 2020, Russia produced RUB 450.7 bln worth of pharmaceutical drugs (manufacturer’s prices, VAT included), which is in monetary terms (rubles) 17.4% higher than in 2019. The production volume in physical terms (units) amounts to 4.4 bln units, with the growth rate of +6.5%. If calculated in minimum dosage units (MDU), the growth rate is higher (+10.7%) and the production volume is 74.6 bln MDUs.

12/10/2020 API Import to Russia (October 2020)

Between January and October 2020, Russia imported RUB 134.1 bln worth of APIs (customs clearance and VAT included), which is in monetary terms (rubles) 20% higher than in 2019. The import volume in physical terms (tons) amounted to 12.1 thousand tons, with the growth rate of +12%.

12/9/2020 Pharmaceutical Drug Import to Russia (October 2020)

Between January and October 2020, Russia imported RUB 404 bln worth of ready-made pharmaceutical drugs (customs clearance and VAT included), which is in monetary terms (rubles) 29.6% lower than in 2019. That is clearly the high base effect, since back in October 2019 the importers were hard at work, preparing for the launch of the labeling system by actively stocking up the warehouses; the import volumes were 2-3 times higher than usual. The growth rates of the in-bulk import are still positive, although only +2.2%, with the import volume of RUB 110.8 bln.

12/7/2020 Pharmaceutical Drug Export from Russia (September and Q1 – Q3 2020)

Between January and September 2020, Russia exported RUB 40.2 bln worth of ready-made pharmaceutical drugs (customs duties included), which is virtually comparable of the total export volume in 2018. The dynamics in monetary terms (rubles) are as high as +23.3%. The export volume in physical terms amounts to 0.83 bln units, with the dynamics of +27.5%.

All news [237]

Our competences

RNC Pharma is focused on providing information about development trends of Russian pharmaceutical market infrastructure component. Our experts also provide services on strategic marketing, such as forecasting, business planning, etc.